AnaptysBio 2025 Q2 Earnings Narrowed Losses Amid Strong Revenue Growth

AnaptysBio reported second-quarter 2025 earnings on August 7, 2025, with revenue more than doubling year-over-year. The company narrowed its net loss per share and overall net loss compared to the prior year period, despite ongoing financial challenges. No formal guidance was provided, and results were in line with expectations for the biotech firm.

Revenue
AnaptysBio's total revenue surged by 102.9% year-over-year to $22.26 million in Q2 2025, with collaboration revenue accounting for the entirety of the increase. This marked a significant jump from $10.97 million in the same period in 2024.

Earnings/Net Income
AnaptysBio narrowed its net loss to $-38.63 million in Q2 2025, a 17.2% reduction from the $-46.66 million loss in Q2 2024. The company’s per-share loss improved by 21.6% to $1.34, showing some progress in curbing losses. However, the firm remains in its 12th consecutive year of losses for this fiscal quarter, underscoring continued financial pressure.

Price Action
The stock price of AnaptysBio has been under pressure in recent trading sessions, with a 3.26% drop on the latest trading day, a 9.77% decline for the week, and a 3.88% loss for the month to date.

Post-Earnings Price Action Review
Following the earnings release, a buy-and-hold strategy initiated after the report yielded mixed results. The strategy returned 53.47%, significantly lower than the 85.18% benchmark return, for an excess return of -31.71%. Despite a moderate Sharpe ratio of 0.13, the strategy experienced a volatility of 68.96% and a maximum drawdown of 0%. While it managed to avoid losses, the strategy’s performance lagged behind market benchmarks.

CEO Commentary
Daniel Faga, President and CEO of AnaptysBio, expressed confidence in the long-term potential of rosnilimab, citing its favorable safety profile and durable efficacy in rheumatoid arthritis through Week 38. He emphasized the completion of enrollment in the ulcerative colitis trial and highlighted plans to initiate a Phase 1b cohort for ANB033 in celiac disease by Q4 2025. Faga also outlined the company’s commitment to transparency, noting the upcoming R&D event to provide more details on its pipeline.

Guidance
The company did not provide specific forward-looking guidance for revenue or losses. However, it remains on track for top-line data from the rosnilimab Phase 2 UC trial in Q4 2025 and anticipates potential six- and 12-month follow-up data in 2026.

Additional News
AnaptysBio announced positive data for rosnilimab through Week 38 in the Phase 2b rheumatoid arthritis trial, including a best-in-class efficacy profile and favorable safety. Enrollment was completed for the global Phase 2 ulcerative colitis trial, with top-line data expected in Q4 2025. The company is also advancing ANB033 in celiac disease, with a Phase 1b cohort planned for Q4 2025 and an R&D event to follow. Additionally, AnaptysBio is positioned to trigger a $75 million commercial milestone from GSK if Jemperli achieves $1 billion in net sales in a calendar year. The company repurchased approximately 9.3% of its shares under its stock repurchase program, signaling confidence in its long-term value.